Roche Holding AG (ROG.VX)
228.00CHF
31 Jul 2013
CHF-3.50 (-1.51%)
CHF231.50
CHF230.00
CHF230.00
CHF226.30
1,426,570
1,420,271
CHF258.60
CHF170.00
About
Overall
| Beta: | 0.90 |
| Market Cap (Mil.): | CHF196,888.30 |
| Shares Outstanding (Mil.): | 862.56 |
| Dividend: | 7.35 |
| Yield (%): | 3.22 |
Financials
| ROG.VX | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 20.44 | 37.93 | 37.76 |
| EPS (TTM): | 11.15 | -- | -- |
| ROI: | 22.90 | 19.48 | 18.76 |
| ROE: | 71.75 | 20.17 | 19.59 |
Alexion shares rise after report of approach by Roche
- Shares of Alexion Pharmaceuticals Inc rose more than 7 percent on Tuesday following a report that Swiss drugmaker Roche Holding AG made an informal approach to the biotech company last week about a takeover.
Alexion shares rise after report of approach by Roche
July 30 - Shares of Alexion Pharmaceuticals Inc rose more than 7 percent on Tuesday following a report that Swiss drugmaker Roche Holding AG made an informal approach to the biotech company last week about a takeover.
Roche tops forecast as new cancer drugs gain momentum
BASEL, Switzerland - Swiss pharmaceuticals firm Roche beat first-half profit forecasts as strong sales of its mainstay cancer drugs and some new treatments supported its view that it can withstand competition from cheap, copycat drugmakers.
UPDATE 3-Roche tops forecast as new cancer drugs gain momentum
* Shares rise 1.0 pct (Adds CEO comments of cardio metabolic research, M&A, updates shares)
Roche tops forecast as new cancer drugs gain momentum
BASEL, Switzerland - Swiss pharmaceuticals firm Roche beat first-half profit forecasts as strong sales of its mainstay cancer drugs and some new treatments supported its view that it can withstand competition from cheap, copycat drugmakers.
Top three drugs boost Roche's first-half earnings
BASEL, Switzerland, July 25 - Strong sales of its top three drugs and new expensive breast cancer treatments helped Roche Holding AG post a bigger-than-expected rise in first-half core earnings of 10 percent.
Roche takes its hunt for a new chairman further afield
ZURICH, July 22 - Swiss drugmaker Roche faces the prospect of hiring an outsider to replace its chairman of 16 years after its most suitable board members turned down the job.
UPDATE 1-Alexion valuation could choke any Roche bid
* Roche seeking financing for potential Alexion bid- sources
Alexion valuation could choke any Roche bid
* Roche seeking financing for potential Alexion bid- sources
Roche seeks financing for potential Alexion bid: sources
NEW YORK/LOS ANGELES - Swiss drugmaker Roche Holding AG is seeking financing for a potential bid for Alexion Pharmaceuticals Inc , a transaction that if successful would be the largest healthcare deal of the year, two people familiar with the matter said on Friday.
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Validea
|
$12.00
|
|
Provider: Wright Reports
|
$506.00
|
|
Provider: Datamonitor
|
$175.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

